BOUDNÝ, Miroslav, Jana ZEMANOVÁ, PrashantKumar KHIRSARIYA, Marek BORSKÝ, Jan VERNER, Jana ČERNÁ, Marek MRÁZ, Alexandra OLTOVÁ, Zuzana JAŠKOVÁ, Michaela ŠPUNAROVÁ, Václav ŠEDA, Yvona BRYCHTOVÁ, Jiří MAYER, Kamil PARUCH a Martin TRBUŠEK. Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations. In 23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere. 2018. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1469384, author = {Boudný, Miroslav and Zemanová, Jana and Khirsariya, PrashantKumar and Borský, Marek and Verner, Jan and Černá, Jana and Mráz, Marek and Oltová, Alexandra and Jašková, Zuzana and Špunarová, Michaela and Šeda, Václav and Brychtová, Yvona and Mayer, Jiří and Paruch, Kamil and Trbušek, Martin}, booktitle = {23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere}, keywords = {CHK1; MU380; CLL; TP53}, language = {eng}, title = {Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations}, year = {2018} }
TY - CONF ID - 1469384 AU - Boudný, Miroslav - Zemanová, Jana - Khirsariya, PrashantKumar - Borský, Marek - Verner, Jan - Černá, Jana - Mráz, Marek - Oltová, Alexandra - Jašková, Zuzana - Špunarová, Michaela - Šeda, Václav - Brychtová, Yvona - Mayer, Jiří - Paruch, Kamil - Trbušek, Martin PY - 2018 TI - Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations KW - CHK1 KW - MU380 KW - CLL KW - TP53 N2 - Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations, Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations. ER -
BOUDNÝ, Miroslav, Jana ZEMANOVÁ, PrashantKumar KHIRSARIYA, Marek BORSKÝ, Jan VERNER, Jana ČERNÁ, Marek MRÁZ, Alexandra OLTOVÁ, Zuzana JAŠKOVÁ, Michaela ŠPUNAROVÁ, Václav ŠEDA, Yvona BRYCHTOVÁ, Jiří MAYER, Kamil PARUCH a Martin TRBUŠEK. Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations. In \textit{23rd Congress of the European Hematology Association, Stockholm, Sweden in HemaSphere}. 2018.
|